# US Heart Failure POC and LOC Devices Market > US Heart Failure POC and LOC Devices Market Research Report By Test Type (Proteomic Testing, Metabolomic Testing, Genomic Testing), By Technology (Microfluidics, Array-based Systems) and By End User (Hospitals & Clinics, Homecare, Specialty Centers, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 2.54% - **2024:** $ 16.61 Million - **2025:** $ 17.03 Million - **2035:** $ 21.88 Million - **Key Players:** Medtronic (US), Abbott (US), Boston Scientific (US), Philips (NL), Bayer (DE), Roche (CH), Johnson & Johnson (US), Siemens Healthineers (DE), Cardinal Health (US) **Report ID:** MRFR/HC/17837-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-heart-failure-poc-and-loc-devices-market-19384 --- ## Market Summary ## **US Heart Failure POC and LOC Devices Market Overview** As per MRFR analysis, the US Heart Failure POC and LOC Devices Market Size was estimated at 14.72 (USD Million) in 2023. The US Heart Failure POC and LOC Devices Market Industry is expected to grow from 17.15(USD Million) in 2024 to 96 (USD Million) by 2035. The US Heart Failure POC and LOC Devices Market CAGR (growth rate) is expected to be around 16.95% during the forecast period (2025 - 2035). ### **Key US Heart Failure POC and LOC Devices Market Trends Highlighted** The US Heart Failure POC (Point-of-Care) and LOC (Laboratory-Optimized Care) Devices Market is currently witnessing significant trends driven by the increasing prevalence of heart failure in the country. The aging population, along with rising obesity rates, contributes to the growing demand for effective heart failure management tools. As per the US Centers for Disease Control and Prevention (CDC), millions of Americans are living with heart failure, pushing healthcare providers to adopt innovative solutions for monitoring and treating this condition. Technological advancements in the devices, including real-time monitoring and remote patient management capabilities, are becoming crucial market drivers. Moreover, there is a major opportunity to enhance patient outcomes through the development of portable and user-friendly devices that facilitate easier home care. The rise of telehealth has also opened new avenues for heart failure monitoring, as patients are now able to receive care remotely, aligning with trends toward increased patient engagement and personalized healthcare. Recent innovations in biosensors and wearable technology are creating exciting opportunities to improve the accuracy of heart failure diagnosis and management. Additionally, regulatory support from bodies like the Food and Drug Administration (FDA) for expedited approval of novel heart failure devices is influencing market dynamics positively.With the focus on cost-effective healthcare solutions, the integration of artificial intelligence in these devices is emerging as a vital trend, allowing for predictive analytics to better manage patient outcomes. Overall, the US Heart Failure POC and LOC Devices Market is evolving rapidly, driven by technological advancements and the growing need for effective management of this complex condition. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Heart Failure POC and LOC Devices Market Drivers** ### **Rising Heart Failure Incidence in the US** The increasing prevalence of heart failure in the United States is a significant driver for the US Heart Failure Point of Care (POC) and Laboratory Onsite Testing (LOC) Devices Market Industry. According to the American Heart Association, about 6.2 million adults in the US have heart failure, and this number is projected to rise due to the aging population and increasing rates of hypertension and diabetes. The Centers for Disease Control and Prevention reports that the number of adults with diagnosed heart failure has increased by over 20 percent in the last decade, necessitating advanced monitoring and diagnostic devices to manage this condition effectively.This growing patient base drives demand for innovative POC and LOC devices that can facilitate timely and accurate management of heart failure, thus significantly contributing to the market growth. Major companies like Abbott Laboratories and Medtronic are at the forefront of developing these technologies, further pushing the market forward as they release new products to cater to this rising need. ### **Technological Advancements in Device Design** Technological advancements play a crucial role in the expansion of the US Heart Failure POC and LOC Devices Market Industry. Innovations such as miniaturization of devices, integration of Artificial Intelligence, and enhanced connectivity options like Bluetooth and mobile health applications are transforming the landscape of heart failure management. According to the Food and Drug Administration, from 2018 to 2022, there has been a significant increase in the approval of novel cardiac monitoring devices, which enhances real-time data collection and patient care.This trend is bolstered by advancements made by established firms such as Philips Healthcare, which has invested heavily in Research and Development to create next-generation monitoring devices that provide better outcomes and patient experiences. These enhanced capabilities are critical in a market that seeks efficiency and effectiveness in managing heart failure. ### **Increased Awareness and Educational Initiatives** Increased awareness of heart failure and its management among both healthcare professionals and the general public is another vital driver for the US Heart Failure POC and LOC Devices Market Industry. Major educational campaigns launched by organizations like the American Heart Association and ongoing training programs for healthcare practitioners have significantly improved the understanding of heart failure. As reported, the National Heart, Lung, and Blood Institute noted that community health initiatives have led to an approximate 15 percent increase in screenings and early detection of heart failure.This rise in awareness directly correlates with more patients seeking out advanced monitoring solutions, driving the demand for POC and LOC devices. Organizations like Boston Scientific also contribute by distributing educational resources, which help create a well-informed patient population willing to invest in innovative medical technologies. ## **US Heart Failure POC and LOC Devices Market Segment Insights** ### **Heart Failure POC and LOC Devices Market Test Type Insights** The Test Type segment within the US Heart Failure POC and LOC Devices Market is increasingly recognized for its pivotal role in advancing cardiac care through innovative testing methodologies. This segment encapsulates various testing approaches, notably Proteomic Testing, Metabolomic Testing, and Genomic Testing, each contributing uniquely to the early detection and management of heart failure. Proteomic Testing is particularly significant as it focuses on the analysis of proteins in the blood, offering insights into the underlying biological processes of heart failure, enabling clinicians to tailor treatment strategies effectively.Metabolomic Testing complements this by examining metabolic profiles, which can reflect physiological changes in heart function, thus helping in identifying at-risk patients who might benefit from proactive interventions. Genomic Testing, on the other hand, delves into the genetic makeup of individuals, highlighting hereditary factors that could predispose patients to heart failure, facilitating personalized medicine approaches. Collectively, these testing types not only enhance patient outcomes but also drive innovations in the US Heart Failure POC and LOC Devices Market.As the need for more accurate and rapid tests increases, the integration of these testing methods represents a transformative opportunity for healthcare providers to improve patient management and develop targeted therapeutics, reinforcing their essential role in the ongoing battle against heart failure. The interplay of these testing modalities is set to support a robust growth trajectory, aligning with the increasing emphasis on precision medicine in the United States. The demand for advanced testing technologies continues to rise as healthcare systems strive to implement more efficient diagnostic pathways, ultimately aiming to enhance the quality of life for individuals living with heart failure.The Test Type segment stands as a critical component in achieving these goals, with a substantial contribution to the broader landscape of heart failure management strategies, driven by ongoing research, technological advancements, and a focus on improving patient care outcomes. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Heart Failure POC and LOC Devices Market Technology Insights** The Technology segment of the US Heart Failure Point of Care (POC) and Laboratory of Care (LOC) Devices Market encompasses advanced systems that are driving significant innovations in heart failure management. Microfluidics technology is particularly vital as it allows for rapid and efficient analysis of minute fluid samples, enabling healthcare professionals to make quick diagnostic decisions. This technology enhances patient outcomes by facilitating timely interventions, thus improving the overall management of heart failure. Meanwhile, Array-based Systems are gaining traction for their ability to process multiple tests simultaneously, making them crucial for comprehensive monitoring and diagnosis.Both technologies are essential for advancing treatment methodologies, as they support personalized healthcare approaches tailored to individual patient needs. Moreover, the increasing incidence of heart failure in the US highlights the growing demand for these technologies, presenting opportunities for further developments and improved accessibility, ultimately fostering market growth within this segment. ### **Heart Failure POC and LOC Devices Market End User Insights** The US Heart Failure POC and LOC Devices Market is experiencing notable growth driven by various end user segments, which play a crucial role in shaping the market landscape. Hospitals and clinics remain vital as they provide acute care and advanced monitoring for heart failure patients, leveraging cutting-edge devices to manage conditions effectively. Homecare services have gained traction due to the rising preference for at-home healthcare, allowing patients to receive continual monitoring and treatment in a more comfortable setting, thereby potentially reducing hospitalization rates.Specialty centers, focusing on specific cardiac conditions, play a significant role by offering specialized care and utilizing advanced technology to enhance patient outcomes. Other channels also contribute to the market by catering to diverse healthcare needs and settings. The growth of telehealth solutions and wearable technologies further supports these end user segments by enabling remote patient monitoring, thus improving accessibility and convenience in managing heart failure. Overall, these segments collectively reflect the increasing demand for innovative heart failure management solutions in the US healthcare system, improving the quality of life for patients while addressing the challenges posed by this chronic condition. ## **US Heart Failure POC and LOC Devices Market Key Players and Competitive Insights** The competitive landscape of the US Heart Failure Point of Care (POC) and Laboratory of Care (LOC) Devices Market is characterized by rapid innovation and a growing demand for effective cardiac care solutions. As heart failure remains a leading cause of morbidity and mortality in the United States, the market has experienced significant expansion, driven by advancements in technology and heightened focus on patient-centric solutions. Diverse players are engaging in strategic collaborations, product launches, and investments aimed at enhancing their offerings and capturing market share. The competition includes established medical device manufacturers as well as emerging companies specializing in novel therapies and diagnostic tools tailored for heart failure management. The dynamic nature of this market underscores the importance of understanding competitive strategies and positioning to navigate the evolving landscape successfully. LivaNova has established a strong presence in the US Heart Failure POC and LOC Devices Market, leveraging its technological innovations and well-regarded expertise in medical devices. The company's strengths lie in its significant investment in research and development, which has led to the creation of advanced devices that cater to the needs of heart failure patients. With a focus on optimizing patient outcomes, LivaNova has developed comprehensive solutions that support both acute and chronic heart failure management, enriching its competitive advantage in an increasingly crowded marketplace. The company's commitment to enhancing accessibility and efficiency in cardiac care further positions it favorably, allowing it to foster lasting relationships with healthcare providers and patients alike. AtriCure operates in the US Heart Failure POC and LOC Devices Market with a commitment to delivering comprehensive solutions for cardiac arrhythmias and heart failure. The company offers a range of innovative products, including radiofrequency ablation technology and advanced surgical devices, specifically designed to improve outcomes for patients suffering from heart failure. AtriCure’s strong market presence is bolstered by its relentless pursuit of innovation and focus on education in the medical community, helping drive adoption of its technologies. In recent years, AtriCure has engaged in strategic mergers and acquisitions to expand its portfolio, enhance its product offerings, and penetrate the market more effectively. This proactive approach, combined with a dedication to clinical research and collaboration with key healthcare stakeholders, positions AtriCure as a formidable player in the US market, with its strengths firmly aligned with addressing the evolving challenges of heart failure care. ### **Key Companies in the US Heart Failure POC and LOC Devices Market Include** ### **US Heart Failure POC and LOC Devices Market Industry Developments** In recent months, the US Heart Failure Point of Care (POC) and Lab on a Chip (LOC) Devices Market has witnessed significant developments with companies such as Medtronic, Abbott Laboratories, and Boston Scientific leading innovations aimed at enhancing patient care and monitoring. Notably, in October 2023, Medtronic announced advancements in its heart failure monitoring technology, contributing to improved patient outcomes and streamlined clinical workflows. Abbott Laboratories has also invested in research to expand its cardiac device portfolio, addressing the growing demand for efficient heart failure management solutions. Over the past two years, there have been notable market expansions, with LivaNova and ZOLL Medical increasing their product availability to cater to rising patient populations. In March 2023, a strategic collaboration between Biotronik and Cleveland HeartLab was announced to enhance diagnostic capabilities for heart failure patients, reflecting a trend towards partnerships for technological advancements in this area. Additionally, the market witnessed a significant upsurge driven by the increasing prevalence of heart conditions and a rising focus on early diagnosis, emphasizing the importance of POC and LOC devices in modern healthcare practices in the US. ## **US Heart Failure POC and LOC Devices Market Segmentation Insights** ### **Heart Failure POC and LOC Devices Market Test Type Outlook** ### **Heart Failure POC and LOC Devices Market Technology Outlook** ### **Heart Failure POC and LOC Devices Market End User Outlook** ## Market Drivers ### Rising Healthcare Expenditure The increasing healthcare expenditure in the US is a significant driver for the heart failure-poc-and-loc-devices market. As healthcare spending continues to rise, estimated to reach $6 trillion by 2027, there is a growing emphasis on investing in advanced medical technologies. This trend is particularly relevant for heart failure management, where the costs associated with hospitalizations and treatments are substantial. The heart failure-poc-and-loc-devices market stands to benefit from this increased investment, as healthcare providers seek cost-effective solutions that improve patient outcomes and reduce overall healthcare costs. Furthermore, the focus on value-based care is likely to drive the adoption of innovative devices that demonstrate clear clinical benefits and cost savings. ### Increased Focus on Home Healthcare The shift towards home healthcare is a notable trend impacting the heart failure-poc-and-loc-devices market. With an aging population and a growing preference for at-home treatment options, healthcare providers are increasingly adopting POC and LOC devices that allow for remote monitoring and management of heart failure. This trend is supported by the desire to reduce hospital readmissions and improve patient quality of life. According to recent studies, home healthcare can lead to a reduction in hospital visits by up to 25%. As a result, the heart failure-poc-and-loc-devices market is likely to see a surge in demand for devices that facilitate home monitoring, enabling patients to manage their conditions more effectively while remaining in the comfort of their homes. ### Rising Prevalence of Heart Failure The increasing incidence of heart failure in the US is a primary driver for the heart failure-poc-and-loc-devices market. According to the American Heart Association, approximately 6.2 million adults in the US are living with heart failure, a figure that is projected to rise as the population ages. This growing patient base necessitates the development and adoption of point-of-care (POC) and location-based (LOC) devices to facilitate timely diagnosis and management. The heart failure POC and LOC devices market is expected to expand as healthcare providers seek innovative solutions for effective patient monitoring and improved outcomes. Furthermore, the economic burden associated with heart failure, estimated at $30 billion annually in the US, underscores the urgent need for efficient management tools, thereby driving demand for advanced devices. ### Technological Innovations in Device Design Innovations in technology are significantly influencing the heart failure-poc-and-loc-devices market. The advent of miniaturized sensors, wireless connectivity, and advanced data analytics has led to the development of sophisticated devices that can monitor heart failure symptoms in real-time. These innovations not only enhance patient engagement but also improve clinical decision-making. For instance, wearable devices that track vital signs and provide alerts to healthcare providers are becoming increasingly popular. The heart failure-poc-and-loc-devices market is likely to benefit from these advancements, as they enable more personalized and proactive care. As technology continues to evolve, the integration of artificial intelligence and machine learning into these devices may further enhance their capabilities, potentially transforming patient management strategies. ### Growing Awareness and Education on Heart Failure The rising awareness and education surrounding heart failure are crucial factors influencing the heart failure-poc-and-loc-devices market. Public health campaigns and educational initiatives have significantly improved understanding of heart failure symptoms, risk factors, and management strategies. This heightened awareness encourages patients to seek timely medical attention and adopt preventive measures, thereby increasing the demand for monitoring devices. As patients become more informed about their conditions, they are more likely to utilize POC and LOC devices to manage their heart failure effectively. The heart failure-poc-and-loc-devices market is expected to grow as healthcare systems prioritize patient education and support, ultimately leading to better health outcomes and reduced healthcare costs. ## Future Outlook The [Heart Failure POC and LOC Devices Market](https://www.marketresearchfuture.com/reports/heart-failure-poc-and-loc-devices-market-10650) is projected to grow at a 2.54% CAGR from 2025 to 2035, driven by technological advancements and increasing patient demand. **New opportunities:** - Development of remote monitoring solutions for chronic heart failure patients. - Integration of AI-driven analytics in device functionality. - Expansion of telehealth services for heart failure management. By 2035, the market is expected to achieve substantial growth, driven by innovation and enhanced patient care. ## Segment Insights ### By Test Type: Proteomic Testing (Largest) vs. Genomic Testing (Fastest-Growing) In the US heart failure-poc-and-loc-devices market, Proteomic Testing holds the largest market share among test types, driven by its advanced capabilities in analyzing proteins that impact heart function. This testing method has gained traction among healthcare providers due to its comprehensive insights that aid in diagnosing heart failure more effectively. Meanwhile, Metabolomic Testing is also notable for its growing presence, allowing for detailed metabolic profiling that supports tailored therapeutic approaches. The growth trends for these test types are significantly influenced by technological advancements and an increased emphasis on personalized medicine. Genomic Testing, in particular, is emerging as the fastest-growing segment, fueled by a heightened focus on genetic factors in heart disease and the ongoing development of cost-effective genomic sequencing technologies. As healthcare shifts towards more individualized treatment plans, the demand for genomic insights is expected to rise markedly in the coming years. Testing: Proteomic Testing (Dominant) vs. Genomic Testing (Emerging) Proteomic Testing is currently the dominant player in the US heart failure-poc-and-loc-devices market, offering in-depth analysis through the identification of proteins associated with heart failure conditions. Its ability to provide critical insights for clinical decisions makes it integral to modern diagnostics. Conversely, Genomic Testing is marked as an emerging force, capturing attention due to its ability to uncover genetic predispositions to heart conditions. This growing interest is fostering its rapid adoption as healthcare professionals move towards more precise and personalized care options. As technology improves, both segments will likely evolve to address emerging needs, making them vital components of heart health strategies. ### By Technology: Microfluidics (Largest) vs. Array-based Systems (Fastest-Growing) In the technology segment of the US heart failure-poc-and-loc-devices market, Microfluidics holds a significant share, being recognized as the largest segment. This innovative technology leverages micro-scale fluid manipulation, allowing for rapid and accurate diagnostics, which is essential in managing heart failure effectively. Array-based systems, on the other hand, are emerging rapidly, capturing the attention of healthcare providers due to their multiplexing capabilities and efficiency in testing multiple biomarkers simultaneously. The growth trend within the technology segment is largely driven by advancements in microfluidic technology, which enhances point-of-care testing by offering faster results and lower sample volumes. Array-based systems are also gaining traction as the demand for comprehensive diagnostic tools increases, facilitating early detection and personalized treatment plans. As healthcare shifts towards a more data-driven approach, both technologies are positioned to transform heart failure management significantly. Technology: Microfluidics (Dominant) vs. Array-based Systems (Emerging) Microfluidics is a dominant technology in the US heart failure-poc-and-loc-devices market, providing precise fluid control that enables miniaturized and efficient diagnostic solutions. Its ability to deliver quick results in small sample sizes enhances patient management and allows for timely interventions. Conversely, Array-based Systems are deemed emerging technologies, offering high-throughput analysis and enabling the simultaneous assessment of various biomarkers, thus streamlining diagnostics. The versatility and efficiency of both technologies position them as essential components within the market, catering to the evolving needs of healthcare professionals and patients alike. ### By End User: Hospitals & Clinics (Largest) vs. Homecare (Fastest-Growing) In the US heart failure-poc-and-loc-devices market, Hospitals & Clinics hold the largest share, reflecting their critical role in providing immediate and advanced patient care. On the other hand, Homecare has emerged as a significant player, harnessing the growing trend of at-home health management. Specialty Centers and Others also contribute to the market dynamics, but with relatively smaller shares. The growth trends in this segment are notably driven by an increasing aging population, rising prevalence of heart failure, and technological advancements in medical devices. Homecare's rapid rise can be attributed to the shift towards patient-centric care models that emphasize convenience and efficiency. Furthermore, the integration of digital health solutions supports this trend, empowering patients to manage their conditions more effectively outside traditional healthcare settings. Hospitals & Clinics (Dominant) vs. Homecare (Emerging) Hospitals & Clinics characterize the dominant force in the US heart failure-poc-and-loc-devices market due to their vast resources and comprehensive patient care capabilities. These settings are equipped with advanced technology and specialized personnel, making them vital for critical interventions. In contrast, Homecare represents an emerging segment that is gaining momentum, driven by patient preferences for receiving care in familiar environments. The rise of telehealth services and portable medical devices is making it easier for patients to monitor their health at home, thus enhancing the appeal of homecare solutions. While Hospitals & Clinics primarily focus on acute care, Homecare aims for proactive and continuous management of heart conditions, illustrating a significant shift in care delivery strategies. ## Competitive Benchmarking The heart failure-poc-and-loc-devices market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of heart failure. Key players such as Medtronic (US), Abbott (US), and Boston Scientific (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Medtronic (US) focuses on innovation through the development of advanced monitoring devices, while Abbott (US) emphasizes strategic partnerships to expand its product offerings. Boston Scientific (US) is actively pursuing mergers and acquisitions to bolster its portfolio, indicating a trend towards consolidation in the market. Collectively, these strategies contribute to a competitive environment that is increasingly characterized by rapid technological evolution and strategic collaborations.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with several key players exerting significant influence. This fragmentation allows for a variety of innovative solutions to emerge, as companies strive to differentiate themselves in a crowded marketplace. In October Medtronic (US) announced the launch of a new remote monitoring system designed to provide real-time data on heart failure patients. This strategic move is likely to enhance patient outcomes and reduce hospital readmissions, aligning with the growing trend towards telehealth solutions. The introduction of such technology not only positions Medtronic (US) as a leader in innovation but also reflects the increasing demand for remote patient management tools in the healthcare sector. In September Abbott (US) entered into a partnership with a leading telemedicine provider to integrate its heart failure monitoring devices with digital health platforms. This collaboration is significant as it enables Abbott (US) to leverage digital health technologies, thereby enhancing patient engagement and adherence to treatment protocols. The partnership underscores the importance of digital transformation in the healthcare landscape, particularly in managing chronic conditions like heart failure. In August Boston Scientific (US) completed the acquisition of a startup specializing in AI-driven analytics for heart failure management. This acquisition is pivotal as it allows Boston Scientific (US) to incorporate advanced data analytics into its product offerings, potentially improving clinical decision-making and patient outcomes. The integration of AI into heart failure management devices is indicative of a broader trend towards data-driven healthcare solutions. As of November current competitive trends in the heart failure-poc-and-loc-devices market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, enhanced patient outcomes, and supply chain reliability. This shift suggests that companies that prioritize R&D and strategic partnerships will be better positioned to thrive in an increasingly complex market. ## Recent News & Developments In recent months, the US Heart Failure Point of Care (POC) and Lab on a Chip (LOC) Devices Market has witnessed significant developments with companies such as Medtronic, Abbott Laboratories, and Boston Scientific leading innovations aimed at enhancing patient care and monitoring. Notably, in October 2023, Medtronic announced advancements in its heart failure monitoring technology, contributing to improved patient outcomes and streamlined clinical workflows. Abbott Laboratories has also invested in research to expand its cardiac device portfolio, addressing the growing demand for efficient heart failure management solutions. Over the past two years, there have been notable market expansions, with LivaNova and ZOLL Medical increasing their product availability to cater to rising patient populations. In March 2023, a strategic collaboration between Biotronik and Cleveland HeartLab was announced to enhance diagnostic capabilities for heart failure patients, reflecting a trend towards partnerships for technological advancements in this area. Additionally, the market witnessed a significant upsurge driven by the increasing prevalence of heart conditions and a rising focus on early diagnosis, emphasizing the importance of POC and LOC devices in modern healthcare practices in the US. ## Report Scope | MARKET SIZE 2024 | 16.61(USD Million) | | --- | --- | | MARKET SIZE 2025 | 17.03(USD Million) | | MARKET SIZE 2035 | 21.88(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 2.54% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Medtronic (US), Abbott (US), Boston Scientific (US), Philips (NL), Bayer (DE), Roche (CH), Johnson & Johnson (US), Siemens Healthineers (DE), Cardinal Health (US) | | Segments Covered | Test Type, Technology, End User | | Key Market Opportunities | Integration of telehealth solutions enhances patient monitoring in the heart failure-poc-and-loc-devices market. | | Key Market Dynamics | Technological advancements and regulatory changes drive innovation in heart failure point-of-care and location-based devices. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the projected market valuation for the US heart failure-poc-and-loc-devices market in 2035?** A: The projected market valuation for 2035 is 21.88 USD Million. **Q: What was the overall market valuation for the US heart failure-poc-and-loc-devices market in 2024?** A: The overall market valuation was 16.61 USD Million in 2024. **Q: What is the expected CAGR for the US heart failure-poc-and-loc-devices market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 2.54%. **Q: Which companies are considered key players in the US heart failure-poc-and-loc-devices market?** A: Key players in the market include Medtronic, Abbott, Boston Scientific, Philips, Bayer, Roche, Johnson & Johnson, Siemens Healthineers, and Cardinal Health. **Q: What are the projected revenues for proteomic testing in the US heart failure-poc-and-loc-devices market?** A: The projected revenues for proteomic testing are expected to rise from 4.98 USD Million to 6.25 USD Million. **Q: How does the revenue for genomic testing change from 2024 to 2035?** A: The revenue for genomic testing is projected to increase from 6.63 USD Million to 9.23 USD Million. **Q: What is the expected revenue growth for microfluidics technology in the market?** A: Microfluidics technology is expected to grow from 6.64 USD Million to 8.56 USD Million. **Q: What are the projected revenues for homecare as an end user in the market?** A: Homecare as an end user is projected to grow from 5.0 USD Million to 6.5 USD Million. **Q: What revenue growth is anticipated for array-based systems technology in the market?** A: Array-based systems technology is anticipated to grow from 9.97 USD Million to 13.32 USD Million. **Q: What is the expected revenue for specialty centers as an end user in the market by 2035?** A: The expected revenue for specialty centers as an end user is projected to increase from 3.0 USD Million to 4.0 USD Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-heart-failure-poc-and-loc-devices-market-19384*